Methods of treating leukemia
AssigneeBioChem Pharma Inc.
InventorsHenriette Gourdeau, Francis J. Giles
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group; and wherein said compound is substantially in the form of the (−) enantiomer.
Claims36
A method for treating a patient with leukemia comprising;
- administering to said patient having chronic myelogenous leukemia or acute myelogenous leukemia, a therapeutically effective amount of a compound having the formula I:
- wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and
- wherein each Rc is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and hydroxy protecting groups;
- wherein said compound is substantially in the form of the (−) enantiomer;
- wherein the step of administering comprises administering to a patient that has been previously treated with Ara-C;
- and
- wherein said compound of formula I is at least 95% free of the (+) form.
A method for treating a patient with leukemia comprising:
- administering to said patient having chronic myelogenous leukemia or acute myelogenous leukemia, a therapeutically effective amount of a compound having the formula I:
- wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and
- wherein each Rc is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and hydroxy protecting groups;
- wherein said compound is substantially in the form of the (−) enantiomer;
- wherein said patient is suffering from a leukemia which is non-responsive to treatment with other chemotherapeutic agents;
- and
- wherein said compound of formula I is at least 95% free of the (+) form.
Dependencies are inferred from the claim text.